[{"id":"753da841-0c33-4a39-9286-8ff2dd2128fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04328740","created_at":"2021-12-16T17:54:55.099Z","updated_at":"2024-07-02T16:35:03.026Z","phase":"Phase 1","brief_title":"Phase 1 Study of Oral TP-1454","source_id_and_acronym":"NCT04328740","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • TP-1454"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 07/08/2020","start_date":" 07/08/2020","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-05-17"}]